The abstract is read at the publisher; the summary is JClub's.
TIMD4 loss worsens DSS-induced colitis in mice, increasing monocyte infiltration into colonic tissue, while TIMD4-derived peptide nanoparticles attenuate disease and P65 phosphorylation.
- Why it matters: TIMD4 is elevated in ulcerative colitis and DSS colitis, but how it shapes intestinal macrophage signaling and monocyte recruitment during inflammation is unclear.
- What they did: Timd4-deficient mice were treated with a CCR2 antagonist or a macrophage-targeted T4(365-378)-NP system; in vitro work tested whether TIMD4 stabilizes the LKB1-STRAD-MO25 complex to activate AMPK and suppress NF-κB chemokine output.
- The result: CCR2 blockade reduced colonic inflammation and monocyte infiltration in Timd4 KO mice, and T4(365-378)-NPs reduced P65 phosphorylation and attenuated DSS colitis, with combination therapy (T4(365-378)-NPs plus anti-α4β7 or anti-TNF-α) improving outcomes beyond monotherapy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.